Schrodinger (SDGR) Competitors $19.29 +0.18 (+0.93%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SDGR vs. NUVL, MRUS, CRSP, TGTX, CYTK, ACAD, KRYS, TLX, ADMA, and AAPGShould you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Telix Pharmaceuticals (TLX), ADMA Biologics (ADMA), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Schrodinger vs. Its Competitors Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics ACADIA Pharmaceuticals Krystal Biotech Telix Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Nuvalent (NASDAQ:NUVL) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Do insiders and institutionals believe in NUVL or SDGR? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 21.0% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer NUVL or SDGR? Nuvalent currently has a consensus price target of $119.36, indicating a potential upside of 50.93%. Schrodinger has a consensus price target of $27.83, indicating a potential upside of 44.30%. Given Nuvalent's stronger consensus rating and higher possible upside, equities analysts plainly believe Nuvalent is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger valuation and earnings, NUVL or SDGR? Schrodinger has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Schrodinger, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-16.14Schrodinger$207.54M6.84-$187.12M-$2.48-7.78 Is NUVL or SDGR more profitable? Nuvalent has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Nuvalent's return on equity of -32.58% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Schrodinger -76.22%-45.70%-24.81% Does the media favor NUVL or SDGR? In the previous week, Nuvalent had 10 more articles in the media than Schrodinger. MarketBeat recorded 16 mentions for Nuvalent and 6 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.52 beat Nuvalent's score of 1.45 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk and volatility, NUVL or SDGR? Nuvalent has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. SummaryNuvalent and Schrodinger tied by winning 8 of the 16 factors compared between the two stocks. Get Schrodinger News Delivered to You Automatically Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SDGR vs. The Competition Export to ExcelMetricSchrodingerMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42B$2.07B$5.76B$9.82BDividend YieldN/AN/A6.66%4.48%P/E Ratio-7.7638.0183.0526.53Price / Sales6.8413.32528.17110.27Price / CashN/A52.0425.7028.92Price / Book4.146.6811.026.61Net Income-$187.12M-$63.67M$3.28B$265.84M7 Day Performance-2.54%-0.42%0.42%-0.09%1 Month Performance-1.24%11.23%10.90%6.78%1 Year Performance-6.10%34.92%53.91%22.77% Schrodinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SDGRSchrodinger2.7176 of 5 stars$19.29+0.9%$27.83+44.3%-9.1%$1.42B$207.54M-7.76790Positive NewsNUVLNuvalent3.2305 of 5 stars$74.05-2.7%$118.91+60.6%-9.7%$5.34BN/A-15.1140News CoveragePositive NewsAnalyst ForecastMRUSMerus3.0036 of 5 stars$65.74-2.6%$88.64+34.8%+30.0%$4.97B$56.23M-11.9537News CoveragePositive NewsCRSPCRISPR Therapeutics3.6013 of 5 stars$54.13-0.3%$71.60+32.3%+10.4%$4.92B$35M-9.97460Analyst RevisionTGTXTG Therapeutics4.4241 of 5 stars$28.53-3.1%$46.25+62.1%+26.6%$4.53B$454.07M77.11290Positive NewsCYTKCytokinetics4.1263 of 5 stars$37.01-3.5%$71.58+93.4%-13.1%$4.43B$18.47M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeGap UpACADACADIA Pharmaceuticals4.0488 of 5 stars$25.32-1.6%$28.88+14.0%+54.9%$4.27B$1.02B19.04510News CoverageAnalyst RevisionKRYSKrystal Biotech4.8211 of 5 stars$146.77-2.5%$210.38+43.3%-23.6%$4.25B$359.21M29.83210Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.13B$516.72M0.00N/AAnalyst RevisionHigh Trading VolumeADMAADMA Biologics4.0125 of 5 stars$17.01-4.4%$27.67+62.6%-0.6%$4.06B$474.17M19.78530Positive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.04B$134.35M0.00600Positive News Related Companies and Tools Related Companies NUVL Competitors MRUS Competitors CRSP Competitors TGTX Competitors CYTK Competitors ACAD Competitors KRYS Competitors TLX Competitors ADMA Competitors AAPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SDGR) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrodinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrodinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SDGR Stock Alerts